Selective cyclooxygenase-2 inhibition: biological and clinical effects.
Conti
F
F
Department of Medicine, Division of Rheumatology, University of Rome La Sapienza, Rome, Italy.
Spinelli
F R
FR
Ossandon
A
A
Valesini
G
G
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D004064:Digestive System / Q000187:drug effects*; D006801:Humans; D007527:Isoenzymes / Q000096:biosynthesis / Q000187:drug effects*; D007668:Kidney / Q000187:drug effects*; D007677:Kidney Function Tests; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases / Q000096:biosynthesis / Q000187:drug effects*; D011453:Prostaglandins / Q000096:biosynthesis; D018570:Risk Assessment; D012680:Sensitivity and Specificity
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007527:Isoenzymes; D008565:Membrane Proteins; D011453:Prostaglandins; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D001241:Aspirin